tirzepatide for the treatment of obstructive sleep apnea and obesity FDA has just approved Zepbound (tirzepatide), the first medication designed to treat both apnoea (OSA) simultaneously. In clinical trials, Zepbound helped reduce breathing disruptions by 50% and Zepbound approved for sleep apnea
Pay in 4 interest-free payments of $6.68 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
Zepbound approved for sleep apnea Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity In a prespecified secondary analysis of the SURMOUNT OSA trial it was found that tirzepatide improves cardiometabolic outcomes in patients with moderate to severe OSA and obesity. tirzepatide #osa #surmount #obesity Sultan Mubarki
Store: www.cleversources.com · Domain: www.cleversources.com






















